Neogen Corporation Share-based Payment Arrangement, Expensed and Capitalized, Amount
Neogen Corporation (NEOG) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $13.40 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Notes › Share-Based Payment Arrangement
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-07-30
- Neogen Corporation share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2024-05-31 was $3.97M, a 38.56% increase year-over-year.
- Neogen Corporation share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2024-02-29 was $3.68M, a 30.83% increase year-over-year.
- Neogen Corporation share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2023-11-30 was $3.51M, a 33.43% increase year-over-year.
- Neogen Corporation share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2023-08-31 was $2.64M, a 41.30% increase year-over-year.
- Neogen Corporation share-based payment arrangement, expensed and capitalized, amount for fiscal 2026 was $13.40M, a 22.54% decline from fiscal 2025.
- Neogen Corporation share-based payment arrangement, expensed and capitalized, amount for fiscal 2025 was $17.30M, a 25.36% increase from fiscal 2024.
- Neogen Corporation share-based payment arrangement, expensed and capitalized, amount for fiscal 2024 was $13.80M, a 35.60% increase from fiscal 2023.
- Neogen Corporation share-based payment arrangement, expensed and capitalized, amount for fiscal 2023 was $10.18M, a 42.26% increase from fiscal 2022.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month as first filed | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month as first filed | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month as first filed | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $13.40M 10-K · filed 2026-07-30 | |||||||
| 2025-05-31 | $17.30M 10-K · filed 2026-07-30 | $17.29M 10-K · filed 2025-07-30 | ||||||
| 2024-05-31 | $3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $7.65M derived: sum of 2 quarters · filed 2026-07-30 | $11.16M derived: sum of 3 quarters · filed 2026-07-30 | $13.80M 10-K · filed 2026-07-30 | $13.77M 10-K · filed 2024-07-30 | |||
| 2024-02-29 | $3.68M 10-Q · filed 2024-04-09 | $7.19M derived: sum of 2 quarters · filed 2024-04-09 | $9.83M 10-Q · filed 2024-04-09 | $12.70M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2023-11-30 | $3.51M 10-Q · filed 2024-01-09 | $6.15M 10-Q · filed 2024-01-09 | $9.02M derived: sum of 3 quarters · filed 2025-07-30 | $11.83M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2023-08-31 | $2.64M 10-Q · filed 2023-10-10 | $5.50M derived: sum of 2 quarters · filed 2025-07-30 | $8.32M derived: sum of 3 quarters · filed 2025-07-30 | $10.95M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2023-05-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | $5.68M derived: sum of 2 quarters · filed 2025-07-30 | $8.31M derived: sum of 3 quarters · filed 2025-07-30 | $10.18M 10-K · filed 2025-07-30 | ||||
| 2023-02-28 | $2.81M 10-Q · filed 2024-04-09 | $5.44M derived: sum of 2 quarters · filed 2024-04-09 | $7.31M 10-Q · filed 2024-04-09 | $9.42M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-11-30 | $2.63M 10-Q · filed 2024-01-09 | $4.50M 10-Q · filed 2024-01-09 | $6.61M derived: sum of 3 quarters · filed 2024-07-30 | $8.21M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-08-31 | $1.87M 10-Q · filed 2023-10-10 | $3.98M derived: sum of 2 quarters · filed 2024-07-30 | $5.58M derived: sum of 3 quarters · filed 2024-07-30 | $7.33M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-05-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $3.72M derived: sum of 2 quarters · filed 2024-07-30 | $5.46M derived: sum of 3 quarters · filed 2024-07-30 | $7.15M 10-K · filed 2024-07-30 | ||||
| 2022-02-28 | $1.61M 10-Q · filed 2023-04-04 | $3.35M derived: sum of 2 quarters · filed 2023-04-04 | $5.04M 10-Q · filed 2023-04-04 | $6.71M derived: sum of 4 quarters · filed 2023-08-15 | ||||
| 2021-11-30 | $1.75M 10-Q · filed 2023-01-09 | $3.44M 10-Q · filed 2023-01-09 | $5.10M derived: sum of 3 quarters · filed 2023-08-15 | $6.68M derived: sum of 4 quarters · filed 2023-08-15 | ||||
| 2021-08-31 | $1.69M 10-Q · filed 2022-09-30 | $3.35M derived: sum of 2 quarters · filed 2023-08-15 | $4.93M derived: sum of 3 quarters · filed 2023-08-15 | $6.45M derived: sum of 4 quarters · filed 2023-08-15 | ||||
| 2021-05-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-15 | $3.25M derived: sum of 2 quarters · filed 2023-08-15 | $4.76M derived: sum of 3 quarters · filed 2023-08-15 | $6.44M 10-K · filed 2023-08-15 | ||||
| 2021-02-28 | $1.58M 10-Q · filed 2022-04-01 | $3.09M derived: sum of 2 quarters · filed 2022-04-01 | $4.77M 10-Q · filed 2022-04-01 | $6.45M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2020-11-30 | $1.51M 10-Q · filed 2021-12-30 | $3.19M 10-Q · filed 2021-12-30 | $4.87M derived: sum of 3 quarters · filed 2022-07-27 | $6.50M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2020-08-31 | $1.68M 10-Q · filed 2021-09-30 | $1.68B 10-Q · filed 2020-09-30 | $3.35M derived: sum of 2 quarters · filed 2022-07-27 | $4.99M derived: sum of 3 quarters · filed 2022-07-27 | $6.61M derived: sum of 4 quarters · filed 2022-07-27 | |||
| 2020-05-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-27 | $3.31M derived: sum of 2 quarters · filed 2022-07-27 | $4.92M derived: sum of 3 quarters · filed 2022-07-27 | $6.47M 10-K · filed 2022-07-27 | ||||
| 2020-02-29 | $1.64M 10-Q · filed 2021-03-31 | $3.25M derived: sum of 2 quarters · filed 2021-03-31 | $4.79M 10-Q · filed 2021-03-31 | $1.31M 10-Q · filed 2020-04-03 | $1.55B derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2019-11-30 | $1.61M 10-Q · filed 2020-12-29 | $3.15M 10-Q · filed 2020-12-29 | $1.40M 10-Q · filed 2019-12-27 | $1.55B derived: sum of 3 quarters · filed 2021-07-30 | $1.55B derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2019-08-31 | $1.54B 10-Q · filed 2020-09-30 | $1.54M 10-Q · filed 2019-09-26 | $1.54B derived: sum of 2 quarters · filed 2021-07-30 | $1.55B derived: sum of 3 quarters · filed 2021-07-30 | $1.55B derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2019-05-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-30 | $6.20M derived: sum of 2 quarters · filed 2021-07-30 | $9.36M derived: sum of 3 quarters · filed 2021-07-30 | $5.54M 10-K · filed 2021-07-30 | ||||
| 2019-02-28 | $4.79M 10-Q · filed 2020-04-03 | $1.31M 10-Q · filed 2019-03-29 | $7.95M derived: sum of 2 quarters · filed 2020-04-03 | $4.14M 10-Q · filed 2020-04-03 | $10.60M derived: sum of 4 quarters · filed 2020-07-30 | |||
| 2018-11-30 | $1.40M 10-Q · filed 2018-12-28 | $2.83M 10-Q · filed 2019-12-27 | $5.80M derived: sum of 3 quarters · filed 2020-07-30 | $6.83M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2018-08-31 | $1.43M 10-Q · filed 2019-09-26 | $2.65M derived: sum of 2 quarters · filed 2020-07-30 | $3.67M derived: sum of 3 quarters · filed 2020-07-30 | $4.94M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2018-05-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-30 | $2.24M derived: sum of 2 quarters · filed 2020-07-30 | $3.51M derived: sum of 3 quarters · filed 2020-07-30 | $4.91M 10-K · filed 2020-07-30 | ||||
| 2018-02-28 | $1.03M 10-Q · filed 2019-03-29 | $2.29M derived: sum of 2 quarters · filed 2019-03-29 | $3.69M 10-Q · filed 2019-03-29 | $5.02M derived: sum of 4 quarters · filed 2019-07-30 | ||||
| 2017-11-30 | $1.26M 10-Q · filed 2018-12-28 | $2.67M 10-Q · filed 2018-12-28 | $3.99M derived: sum of 3 quarters · filed 2019-07-30 | $5.19M derived: sum of 4 quarters · filed 2019-07-30 | ||||
| 2017-08-31 | $1.40M 10-Q · filed 2018-10-05 | $2.73M derived: sum of 2 quarters · filed 2019-07-30 | $3.93M derived: sum of 3 quarters · filed 2019-07-30 | $5.15M derived: sum of 4 quarters · filed 2019-07-30 | ||||
| 2017-05-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2019-07-30 | $2.53M derived: sum of 2 quarters · filed 2019-07-30 | $3.75M derived: sum of 3 quarters · filed 2019-07-30 | $5.26M 10-K · filed 2019-07-30 | ||||
| 2017-02-28 | $1.20M 10-Q · filed 2018-03-29 | $2.42M derived: sum of 2 quarters · filed 2018-03-29 | $3.93M 10-Q · filed 2018-03-29 | |||||
| 2016-11-30 | $1.22M 10-Q · filed 2018-01-05 | $2.73M 10-Q · filed 2018-01-05 | ||||||
| 2016-08-31 | $1.52M 10-Q · filed 2017-09-29 | |||||||
| 2016-05-31 | $5.47M 10-K · filed 2018-07-27 | |||||||
| 2016-02-29 | $1.46M 10-Q · filed 2017-03-31 | $2.71M derived: sum of 2 quarters · filed 2017-03-31 | $4.01M 10-Q · filed 2017-03-31 | |||||
| 2015-11-30 | $1.25M 10-Q · filed 2016-12-29 | $2.54M 10-Q · filed 2016-12-29 | ||||||
| 2015-08-31 | $1.30M 10-Q · filed 2016-09-30 | |||||||
| 2015-05-31 | $4.45M 10-K · filed 2017-07-28 | |||||||
| 2014-05-31 | $3.69M 10-K · filed 2016-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |